Recent developments in small molecule therapies for renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Renal cell carcinoma (RCC) is the most common kidney cancer globally and the 10th most common cancer worldwide.
• Current RCC treatments primarily involve tyrosine kinase inhibitors (TKIs).
• Combination therapies and novel small molecule targets represent the forefront of RCC drug development.

Purpose of the Study:

• To review the three major streams in the development of small molecule drugs for renal cell carcinoma (RCC).
• To highlight current TKI therapies, emerging combination treatments with immune checkpoint inhibitors, and next-generation small molecules.

Main Methods:

• Literature review of current and emerging small molecule therapies for RCC.
• Analysis of clinical trial trends and novel therapeutic targets.
• Synthesis of information on TKIs, PD-1/PD-L1 inhibitors, and other small molecules.

Main Results:

• Tyrosine kinase inhibitors (TKIs) are the current standard for RCC treatment.
• Combination therapies involving TKIs and immune checkpoint inhibitors (PD-1/PD-L1) are in late-stage clinical trials.
• Emerging small molecule therapies targeting indoleamine-2,3-dioxygenase (IDO1), glutaminase, C-X-C chemokine receptor 4 (CXCR4), and transglutaminase 2 (TG2) show promise.

Conclusions:

• Small molecule drug development for RCC is advancing through multiple therapeutic avenues.
• Combination therapies and novel targeted agents are crucial for improving RCC treatment outcomes.
• The identified streams represent the future landscape of small molecule therapeutics for kidney cancer.